Endocan-1 concentrations in maternal and fetal plasma and placentae in pre-eclampsia in the third trimester of pregnancy

Cytokine

Volumn 74, Issue 1, 2015, Pages 152-156

  Hentschke, Marta Ribeiro ^a   Lucas, Luiza Silveira ^a   Mistry, Hiten D ^b   Pinheiro da Costa, Bartira E ^a   Poli de Figueiredo, Carlos E ^a  

^a PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

Endothelium; ESM 1; Gestation induced hypertension; Proteoglycan

Indexed keywords

ENDOCAN 1; PROTEOGLYCAN; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; ESM1 PROTEIN, HUMAN; TUMOR PROTEIN;

ADULT; ARTICLE; BIRTH WEIGHT; BRAZIL; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FETUS PLASMA; GESTATIONAL AGE; HUMAN; HUMAN TISSUE; MATERNAL PLASMA; MOLECULAR PATHOLOGY; OBSERVATIONAL STUDY; PLACENTA WEIGHT; PLASMA; PREECLAMPSIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEINURIA; QUANTITATIVE ANALYSIS; SYSTOLIC BLOOD PRESSURE; THIRD TRIMESTER PREGNANCY; BLOOD; CHEMISTRY; FETUS BLOOD; PLACENTA; PREGNANCY; UPREGULATION; YOUNG ADULT;

ADULT; BIOMARKERS; BRAZIL; CASE-CONTROL STUDIES; FEMALE; FETAL BLOOD; GESTATIONAL AGE; HUMANS; NEOPLASM PROTEINS; PLACENTA; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY TRIMESTER, THIRD; PROTEOGLYCANS; UP-REGULATION; YOUNG ADULT;

EID: 84930506563     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2015.04.013     Document Type: Article

References (38)

1. Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol 2009, 33:130-137.
2. LaMarca B.D., Gilbert J., Granger J.P. Recent progress toward the understanding of the pathophysiology of hypertension during preeclampsia. Hypertension 2008, 51:982-988.
3. Lamarca B. The role of immune activation in contributing to vascular dysfunction and the pathophysiology of hypertension during preeclampsia. Minerva Ginecol 2010, 62:105-120.
4. Gilbert J.S., Ryan M.J., LaMarca B.B., Sedeek M., Murphy S.R., Granger J.P. Pathophysiology of hypertension during preeclampsia: linking placental ischemia with endothelial dysfunction. Am J Physiol Heart Circ Physiol 2008, 294:H541-H550.
5. Laresgoiti-Servitje E. A leading role for the immune system in the pathophysiology of preeclampsia. J Leukoc Biol 2013, 94:247-257.
6. Jonsson Y., Ruber M., Matthiesen L., Berg G., Nieminen K., Sharma S., et al. Cytokine mapping of sera from women with preeclampsia and normal pregnancies. J Reprod Immunol 2006, 70:83-91.
7. Vince G.S., Starkey P.M., Austgulen R., Kwiatkowski D., Redman C.W. Interleukin-6, tumour necrosis factor and soluble tumour necrosis factor receptors in women with pre-eclampsia. Br J Obstet Gynaecol 1995, 102:20-25.
8. Freitas Fernando Rotinas em Obstetrícia 2011, 904. Artmed, Porto Alegre. 6th ed.
9. Lassalle P., Molet S., Janin A., Heyden J.V., Tavernier J., Fiers W., et al. ESM-1 is a novel human endothelial cell-specific molecule expressed in lung and regulated by cytokines. J Biol Chem 1996, 271:20458-20464.
10. Depontieu F., de Freitas Caires N., Gourcerol D., Giordano J., Grigoriu B., Delehedde M., et al. Development of monoclonal antibodies and ELISA specific for the mouse vascular Endocan-1. J Immunol Methods 2012, 378:88-94.
11. Scherpereel A., Gentina T., Grigoriu B., Senechal S., Janin A., Tsicopoulos A., et al. Overexpression of Endocan-1 induces tumor formation. Cancer Res 2003, 63:6084-6089.
12. Bechard D., Meignin V., Scherpereel A., Oudin S., Kervoaze G., Bertheau P., et al. Characterization of the secreted form of endothelial-cell-specific molecule 1 by specific monoclonal antibodies. J Vasc Res 2000, 37:417-425.
13. De Freitas Caires N., Legendre B., Parmentier E., Scherpereel A., Tsicopoulos A., Mathieu D., et al. Identification of a 14kDa Endocan-1 fragment generated by cathepsin G, a novel circulating biomarker in patients with sepsis. J Pharm Biomed Anal 2013, 78-79:45-51. [Research Support, Non-U.S. Gov'tValidation Studies].
14. Grigoriu B.D., Depontieu F., Scherpereel A., Gourcerol D., Devos P., Ouatas T., et al. Endocan-1 expression and relationship with survival in human non-small cell lung cancer. Clin Cancer Res 2006, 12:4575-4582.
15. Perey L., Benhattar J., Peters R., Jaunin P., Leyvraz S. High tumour contamination of leukaphereses in patients with small cell carcinoma of the lung: a comparison of immunocytochemistry and RT-PCR. Br J Cancer 2001, 85:1713-1721.
16. Ziol M., Sutton A., Calderaro J., Barget N., Aout M., Leroy V., et al. ESM-1 expression in stromal cells is predictive of recurrence after radiofrequency ablation in early hepatocellular carcinoma. J Hepatol 2013, 59:1264-1270.
17. Nault J.C., Guyot E., Laguillier C., Chevret S., Ganne-Carrie N., N'Kontchou G., et al. Serum proteoglycans as prognostic biomarkers of hepatocellular carcinoma in patients with alcoholic cirrhosis. Cancer Epidemiol Biomark Prevent 2013, 22:1343-1352.
18. Kang Y.H., Ji N.Y., Lee C.I., Lee H.G., Kim J.W., Yeom Y.I., et al. ESM-1 silencing decreased cell survival, migration, and invasion and modulated cell cycle progression in hepatocellular carcinoma. Amino Acids 2011, 40:1003-1013.
19. Chen L.Y., Liu X., Wang S.L., Qin C.Y. Over-expression of the Endocan-1 gene in endothelial cells from hepatocellular carcinoma is associated with angiogenesis and tumour invasion. J Int Med Res 2010, 38:498-510.
20. Xiang X., Zhao W.B., Wang X. Expression of ESM-1 in hepatocellular carcinoma is associated with angiogenesis and tumor invasion. Zhonghua Gan Zang Bing Za Zhi 2009, 17:661-664.
21. Huang G.W., Tao Y.M., Ding X. Endocan-1 expression correlated with poor survival in human hepatocellular carcinoma. Dig Dis Sci 2009, 54:389-394.
22. Kim J.H., Park M.Y., Kim C.N., Kim K.H., Kang H.B., Kim K.D., et al. Expression of endothelial cell-specific molecule-1 regulated by hypoxia inducible factor-1alpha in human colon carcinoma: impact of ESM-1 on prognosis and its correlation with clinicopathological features. Oncol Rep 2012, 28:1701-1708.
23. Kang Y.H., Ji N.Y., Han S.R., Lee C.I., Kim J.W., Yeom Y.I., et al. ESM-1 regulates cell growth and metastatic process through activation of NF-kappaB in colorectal cancer. Cell Signal 2012, 24:1940-1949.
24. Ji N.Y., Kim Y.H., Jang Y.J., Kang Y.H., Lee C.I., Kim J.W., et al. Identification of endothelial cell-specific molecule-1 as a potential serum marker for colorectal cancer. Cancer Sci 2010, 101:2248-2253.
25. Zuo L., Zhang S.M., Hu R.L., Zhu H.Q., Zhou Q., Gui S.Y., et al. Correlation between expression and differentiation of Endocan-1 in colorectal cancer. World J Gastroenterol 2008, 28:4562-4568.
26. Paulus P., Jennewein C., Zacharowski K. Biomarkers of endothelial dysfunction: can they help us deciphering systemic inflammation and sepsis?. Biomarkers 2011, 16(Suppl 1):S11-S21.
27. Scherpereel A., Depontieu F., Grigoriu B., Cavestri B., Tsicopoulos A., Gentina T., et al. Endocan-1, a new endothelial marker in human sepsis. Crit Care Med 2006, 34:532-537.
28. Filep J.G. Endocan-1 or endothelial cell-specific molecule-1: a novel prognostic marker of sepsis?. Crit Care Med 2006, 34:574-575.
29. Palmiere C., Augsburger M. Endocan-1 measurement for the postmortem diagnosis of sepsis. Leg Med (Tokyo) 2014, 16:1-7.
30. Tadzic R., Mihalj M., Vcev A., Ennen J., Tadzic A., Drenjancevic I. The effects of arterial blood pressure reduction on Endocan-1 and soluble endothelial cell adhesion molecules (CAMs) and CAMs ligands expression in hypertensive patients on Ca-channel blocker therapy. Kidney Blood Press Res 2013, 37:103-115.
31. Janke J., Engeli S., Gorzelniak K., Feldpausch M., Heintze U., Bohnke J., et al. Adipose tissue and circulating endothelial cell specific molecule-1 in human obesity. Horm Metab Res 2006, 38:28-33.
32. Joost S.J.W., Gerarda W., Sicco S., Marielle V.P., Marijke F. New prognostic marker for the risk to develop early-onset preeclampsia. Preg Hypertens [Poster] 2013, 3:94-95.
33. Cross S.B.I., Duzyj C., Shook L., McCarthy M., Hardy J., Zhao G., et al. Endocan-1 (ESM-1): a novel soluble endothelial cell injury marker in preeclampsia (PE) and intrauterine growth restriction (IUGR). Am J Obstet Gynecol 2013, 208(1 SUPPL.1):S276.
34. Adekola H., Romero R., Chaemsaithong P., Korzeniewski S.J., Dong Z., Yeo L., et al. Endocan-1, a putative endothelial cell marker, is elevated in preeclampsia, decreased in acute pyelonephritis, and unchanged in other obstetrical syndromes. J Matern Fetal Neonat Med 2014, 28:1-12. [Epub ahead of print].
35. Yuksel MA1, Tuten A, Oncul M, Acikgoz AS, Temel Yuksel I, Toprak MS, et al. Serum Endocan-1 concentration in women with pre-eclampsia. Arch Gynecol Obstet 2014 [Epub ahead of print]. http://dx.doi.org/10.1007/s00404-014-3605-x.
36. Report of the national high blood pressure education program working group on high blood pressure in pregnancy. Am J Obstet Gynecol 2000;183:S1-S22.
37. VI Diretrizes Brasileiras de Hipertensão. Arq Bras Cardiol 2010, 95(Suppl. 1):1-51. Sociedade Brasileira de Cardiologia/Sociedade Brasileira de Hipertensão/Sociedade Brasileira de Nefrologia.
38. Mikkelsen M.E., Shah C.V., Scherpereel A., et al. Lower erum endocan levels are associated with the development of acute lung injury after major trauma. J Crit Care 2012, 27:522.e11-7.